| Related Articles |
Post Hoc Assessment of Time to Clinical Response Among Adults Hospitalized with Community-Acquired Bacterial Pneumonia Who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials.
Open Forum Infect Dis. 2020 May;7(5):ofaa145
Authors: Lodise T, Colman S, Stein DS, Fitts D, Goldberg L, Alexander E, Scoble PJ, Schranz J
Abstract
Time to clinical response, a proxy for hospital "discharge readiness," was compared between CABP inpatients who received lefamulin or moxifloxacin in the Lefamulin Evaluation Against Pneumonia (LEAP) trials. The analysis included 926 inpatients. A short and comparable median time to clinical response (4 days) was observed in both treatment groups.
PMID: 32462049 [PubMed]